Noninvasive diagnostics is a technique of the detection of cancer disease through less incision into body. Early detection of cancer and treatment is very crucial for the long-term survival. It helps in providing faster diagnosis solution, early detection, better condition to the patients, and important assistance to the clinician. This is the minimal pain procedure with accurate diagnose results.
According to data published in 2017 by Genome Biology Article, there are two types of studies being done for non-invasive cancer diagnostics, including general cancer detection with the help of description of circulation tumor DNA and studies of specific type of cancer by development of bio-markers. These studies are helping manufacturers for developing advanced detection kits for cancer.
Rising prevalence of cancer is attributed to propel the growth of non-invasive cancer diagnostic market. Cancer is the major cause of death across the world, affecting economies of several countries.
According to estimation of American Cancer Society, in 2013, approximately 16,60,290 new cases of cancers were diagnosed.
According to the estimation of National Cancer Institute (NIH), the number of cancer incidences were around 439.2 per 100,000 person between 2011 to 2015 and around 15.5 million individuals were cancer survivors in the United States, which is estimated to be 20.3 million individuals in 2026.
According to the estimation of U.S. Breast Cancer Surveillance Consortium (BCSC), the rate of cancer detection were around 25.3 per thousand person in 2005. which increased to 34.7 per thousand person in 2013.
Moreover, governmental and non government organizations are also spreading awareness for different types of cancer as well as conducting several screening programme. Furthermore, there are many key players participating in improving diagnosis rate by conveying the benefits of early detection of cancer. In addition, rising expenditure for further research and development is attributed to boost the market growth.
Geographically, non-invasive cancer diagnostics market can be segmented as North America, Europe, Asia Pacific, and LAMEA. North America is expected to be dominant in the market, followed by Europe, owing to factors including rising prevalence of cancer, increasing demand of noninvasive diagnostics techniques, increasing awareness towards various cancer diseases and the availability of alternative treatments. Moreover, continuous research in oncology segment has led to the positive impact on the market.
Asia-Pacific is predicted to grow in the non-invasive cancer diagnostics market, attributed to factors including developing health-care infrastructure, rising geriatric population, and growing awareness regarding the advantages of early diagnosis of disease. Moreover, advanced techniques in cancer detection is anticipated to propel the market growth. Furthermore, changing lifestyle and increasing consumption of alcohol and tobacco are major factors contributing to increasing cancer burden. However, high cost of cancer treatment may impede the non-invasive cancer diagnostics market.
Latin America and Middle East & Africa is expected to growing market due to factors such as rising concern regarding cancer across world and huge investment in this region by several leading companies due to large untapped market. This region represents immense opportunity for several global players because of the large unmet needs of cancer patients. In view of all relating factors, non-invasive cancer diagnostics treatment market is growing in this region.
Major global players in the market are: Roche Diagnostics, Quidel, Compugen, DiagnoCure, Immunicon Corporation, Abbott Molecular, GE Healthcare, Affymetrix Inc, Digene Corporation and Precision Therapeutics.
A leading genetic testing company, Natera, Inc., launched ctDNA technology based product Sigatera for the detection of cancer disease, in 2017. Similar strategies has been adopted by other industrial key players. Exosome Diagnostics, Inc announced the launch of ExoDx Prostate (IntelliScore) test. The test was designed to evaluate possible risk for prostate cancer with the help of genetic data from urine sample.
o Breast Cancer
o Blood Cancer
o Lung Cancer
o Solid Tumors
o Molecular Diagnosis
o Clinical Chemistry
o North America (U.S and Canada)
o Europe (Germany, France, Italy and Rest of Europe)
o Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
o LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)